Prime Medicine closes public offering of about $143.7M with full option exercise
FROM THE WIRE · GLOBENEWSWIRE.COM
CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA new share offering at a set price can weigh on the stock through dilution.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The offering includes 41,071,428 shares, including the option for 5,357,142 additional shares.
- 02The public offering price was $3.50 per share.
- 03Gross proceeds were approximately $143.7 million, before underwriting discounts and expenses.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets